EP0565658A1 - Verbenone, having antielastase activity, against pulmonary emphysema - Google Patents
Verbenone, having antielastase activity, against pulmonary emphysemaInfo
- Publication number
- EP0565658A1 EP0565658A1 EP92920465A EP92920465A EP0565658A1 EP 0565658 A1 EP0565658 A1 EP 0565658A1 EP 92920465 A EP92920465 A EP 92920465A EP 92920465 A EP92920465 A EP 92920465A EP 0565658 A1 EP0565658 A1 EP 0565658A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- verbenone
- activity
- pulmonary emphysema
- medicament
- solutions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the use of a terpene derivative, namely (IS) (-)-4,6,6- trimethylbicyclo-(3,1,1)-hept-3-ene-2-one (hereinafter named verbenone) of formula
- the invention also relates to a verbenone-cyclodextrin complex and the pharmaceutical compositions containing it.
- Pulmonary emphysema is a progressive respiratory disorder characterized by an abnormal and permanent increase in the volume of the air spaces located distally to the terminal bronchiole, with destruction of the alveolar septum.
- a number of experimental and clinical data generally ascribe the emphysema pathogenesis to an unbalance of the protease-antiprotease ratio at the alveolus level.
- alveolar proteases exert an essential activity, which is the lysis of cell fragments, thrombi and particles. Said activity is counterbalanced be endogenous antiproteases (£ ⁇ -l antitrypsin [o lAT], ( -2 macroglobulin [ ⁇ -2M] , Bronchial Mucus Inhibitor [B.M.I.]), which protect the pulmonary tissue from the protease action.
- the loss of the normal balance between proteases and antiproteases can be attributed to three factors: 1) congenital lack in antiproteases (particularly f ⁇ -lAT); 2) excessive protease release at the alveolus level; 3) partial inactivation of antiproteases (Ck-1AT) in the presence of a normal or enhanced protease production. Said factors are generally worsened by tobacco smoke.
- alveolar proteases leukocytal elastase proves to have the most marked digestive activity on all the pulmonary connective components, particularly on elastin, the fibres of which constitute the alveolar septa, thus giving lung the functional elasticity.
- verbenone exerts an unpredictable antielestase activity at the lung level, and, due to said activity, it is useful in the treatment of emphysema.
- Verbenone is a monoterpene derivative having antiinflammatory and mucolytic activities and it is used as a mucolytic and fluidifying agent in the acute and chronic disorders of the respiratory tract.
- verbenone showed a surprising inhibiting activity on the elastase action, particularly on the neutrophylic one. Said activity was unforeseeable from the pharmacological and clinical studies which evidenced the mucolytic and antiinflammatory activities of verbenone and the use thereof in therapy.
- pulmonary emphysema can be favoured, or worsened, by the simultaneous presence of other pulmonary disorders, such as bronchitis and/or pneumonia, other infective forms, asthma, which involve obstructions of the respiratory tract; therefore a medicament which can at the same time have antiinflammatory and mucolytic activities and protect elastin of the alveolar septa is obviously useful.
- Tests were carried out ⁇ n vitro to evaluate verbenone activity on the release of neutrophilic elastin from polymorphonuclear granules. Said tests evidenced the marked antielastase activity of verbenone, which activity is not dose-related nor cytotoxic.
- Polymorphonuclear phagocytes were separate starting from heparinized peripheral blood (60 cc) fro healthy volunteers or from buffy coats (leukocytes an platelets enrichments).
- Neutrophilic polymorphonuclears were separated b means of a 6% colloidal dextran gradient, then the erythrocytes were lysated with an ammonium chloride solution. Neutrophilic elastase release
- the plate was centrifuged and 100 ⁇ l of supernatant were collected and incubated for 60-120' at 37 ⁇ C with a specific substrate for the neutrophilic elastase (methoxysuccinyl-ala-ala-pro-val-p-Na) to a 1 mM final concentration.
- the reaction was stopped by adding 50 ⁇ l of 1 N acetic acid and reading was carried out by means of a multiscan photometer at a 405 nm wave length.
- the values of the absorbance of samples challenged with fMLP were compared to those from unchallenged cells, to obtain a ⁇ value corresponding to the amount of neutrophilic elastase released following to challenge. Any interferences of verbenone on the neutrophilic elastase release were tested by addition of different concentrations of the medicament directly to the cell suspension during the test. The results are shown in Table 1.
- verbenone is used as the active ingredient for the preparation of a medicament useful for the treatment of pulmonary emphysema.
- verbenone has the drawbacks to be insoluble in water and to have a very unpleasant taste, therefore it cannot be used for aqueous liquid pharmaceutical forms, such as syrups, oral solutions, nasal drops, aqueous solutions for aerosol and nebulization.
- the verbenone-cyclodextrin complex has high water solubility and, moreover, verbenone unpleasant taste is no more perceptible. Therefore, the verbenone-cyclodextrin complex is a further object of invention.
- a further advantage of the complex of the invention is provided by its increased bioavailability.
- the pharmaceutical forms comprising the verbenone- cyclodextrin complex can be prepared, for example, according to the methods described in "Remington's Pharmaceutical Sciences Handbook", Ralph Pub. Co., USA.
- Examples of pharmaceutical forms are capsules, pills, tablets, sugar-coated pills, granulates, syrups, drinkable solutions, nasal drops, solutions for aerosol or inhalation, suppositories, injectable solutions or suspensions both for the intravenous and the intramuscular routes.
- the dosages will depend on the severity of the disorder, the age, weight and sex of the patient and on the clinician's advise.
- Examples of dosages comprise single or repeated administrations of the medicament containing verbenone or the verbenone-cyclodextrin complex so as to attain a daily dosage from 10 to 500 mg of the active ingredient.
- the preparation of the verbenone-cyclodextrin complex is illustrated in the following examples.
- a ⁇ -ciclodextrin amount equal to 0.1 mole is weighed and placed into a mortar of suitable size.
- the obtained complex is in form of a flowing powder which is completely odourless.
- the obtained product is an equimolar mixture (1:1) of verbenone and cyclodextrin (50 g theoretical, 49 g found).
- ⁇ -Cyclodextrin ⁇ -Cyclodextrin are dispersed in 500 ml of distilled water (50 mmoles) and the solution is heated to 65 e C. under stirring, until complete dissolution. solution, with stirring. The mixture is left to cool t room temperature with stirring for 60 minutes, then i is kept at +4°C for 6 hours.
- the solid phase is recovered by filtration and th solid is placed into a convection oven at 40°C for 18 hours, to obtain 64 g of a white powdery product, containing from 11.3 to 12.0% w/w of L-verbenone. Yield - 84.65%.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Abstract
On décrit l'utilisation d'un dérivé du terpène dans la préparation d'un médicament qui est utile pour le traitement de l'emphysème pulmonaire.The use of a terpene derivative in the preparation of a medicament which is useful for the treatment of pulmonary emphysema is described.
Description
VERBENONE, HAVING ANTIELASTASE ACTIVITY.AGAINST PULMONARY EMPHYSEMA
The present invention relates to the use of a terpene derivative, namely (IS) (-)-4,6,6- trimethylbicyclo-(3,1,1)-hept-3-ene-2-one (hereinafter named verbenone) of formula
for the preparation of a medicament useful in the treatment of pulmonary emphysema. The invention also relates to a verbenone-cyclodextrin complex and the pharmaceutical compositions containing it.
Pulmonary emphysema is a progressive respiratory disorder characterized by an abnormal and permanent increase in the volume of the air spaces located distally to the terminal bronchiole, with destruction of the alveolar septum.
A number of experimental and clinical data generally ascribe the emphysema pathogenesis to an unbalance of the protease-antiprotease ratio at the alveolus level. Under normal conditions, alveolar proteases exert an essential activity, which is the lysis of cell fragments, thrombi and particles. Said activity is counterbalanced be endogenous antiproteases (£\-l antitrypsin [o lAT], ( -2 macroglobulin [<Λ-2M] ,
Bronchial Mucus Inhibitor [B.M.I.]), which protect the pulmonary tissue from the protease action. The loss of the normal balance between proteases and antiproteases can be attributed to three factors: 1) congenital lack in antiproteases (particularly fλ-lAT); 2) excessive protease release at the alveolus level; 3) partial inactivation of antiproteases (Ck-1AT) in the presence of a normal or enhanced protease production. Said factors are generally worsened by tobacco smoke. Among alveolar proteases, leukocytal elastase proves to have the most marked digestive activity on all the pulmonary connective components, particularly on elastin, the fibres of which constitute the alveolar septa, thus giving lung the functional elasticity. Besides the traditional treatments, which cannot remedy the elastin destruction, therapies have been studied to restore elastin synthesis and to protect elastin from elastases action. Satisfactory experimental results were obtained both administering human IX-1 T intravenously and stimulating the hepatic synthesis thereof by administration of danatrol, which is a testosterone semi-synthetic derivative. However, both methods suffers from drawbacks, the first method being particularly complex and expensive, whereas the second has antigonadotropinic effects.
Therefore there is the need for a medicament exerting an antielastase activity, directly or indi¬ rectly, and also having poor side-effects.
Now it has been found that verbenone exerts an unpredictable antielestase activity at the lung level, and, due to said activity, it is useful in the
treatment of emphysema.
Verbenone is a monoterpene derivative having antiinflammatory and mucolytic activities and it is used as a mucolytic and fluidifying agent in the acute and chronic disorders of the respiratory tract.
As a consequence of further researches, verbenone showed a surprising inhibiting activity on the elastase action, particularly on the neutrophylic one. Said activity was unforeseeable from the pharmacological and clinical studies which evidenced the mucolytic and antiinflammatory activities of verbenone and the use thereof in therapy.
The use of verbenone in the treatment of pulmonary emphysema is extremely advantageous. In fact, pulmonary emphysema can be favoured, or worsened, by the simultaneous presence of other pulmonary disorders, such as bronchitis and/or pneumonia, other infective forms, asthma, which involve obstructions of the respiratory tract; therefore a medicament which can at the same time have antiinflammatory and mucolytic activities and protect elastin of the alveolar septa is obviously useful.
Tests were carried out ^n vitro to evaluate verbenone activity on the release of neutrophilic elastin from polymorphonuclear granules. Said tests evidenced the marked antielastase activity of verbenone, which activity is not dose-related nor cytotoxic.
The results from said tests are reported hereinbelow.
Separation of neutrophilic polymorphonuclears
Polymorphonuclear phagocytes were separate starting from heparinized peripheral blood (60 cc) fro healthy volunteers or from buffy coats (leukocytes an platelets enrichments).
Neutrophilic polymorphonuclears were separated b means of a 6% colloidal dextran gradient, then the erythrocytes were lysated with an ammonium chloride solution. Neutrophilic elastase release
100 μl of cells at a concentration of 1x10 /ml, pretreated with cytochalasin B (5 μg/ml) for 10', were incubated for 20" at 37CC in a microtiter plate in the presence or in the absence of 50 μl of a challenge consisting of fMLP (formyl-methionyl-leucyl-peptide) at a 10 molar final concentration. After said incubation, the plate was centrifuged and 100 μl of supernatant were collected and incubated for 60-120' at 37βC with a specific substrate for the neutrophilic elastase (methoxysuccinyl-ala-ala-pro-val-p-Na) to a 1 mM final concentration. The reaction was stopped by adding 50 μl of 1 N acetic acid and reading was carried out by means of a multiscan photometer at a 405 nm wave length. The values of the absorbance of samples challenged with fMLP were compared to those from unchallenged cells, to obtain a Δ value corresponding to the amount of neutrophilic elastase released following to challenge. Any interferences of verbenone on the neutrophilic elastase release were tested by addition of different concentrations of the medicament directly to the cell suspension during the test.
The results are shown in Table 1.
TABLE 1 Modulation of the elastase release from neutrophilic polymorphonuclears by addition of verbenone to the cells during the test, at different concentrations.
% inhibition compared to the control
Control Verb. 1 mM 90% Verb. 0,1 mM 86% Verb. 10 μM 94% Verb. 1 μM 94% Verb. 0,1 μM 92% Verb. 10 nM 89% Verb. 1 nM 83% Verb..0,1 nM 96% Verb. 10 pM 94%
This marked inhibiting activity is unlikely to be ascribed to a toxic action of the medicament on the cells. In fact the cell viability, as repeatedly evaluated by the tripan bleu exclusion test, turned out to be always higher than 90% after incubation of the cells with verbenone in concentrations varying from 1 mM to 10 pM.
From the industrial point of view, verbenone is used as the active ingredient for the preparation of a medicament useful for the treatment of pulmonary emphysema.
For the preparation medicaments, verbenone has the drawbacks to be insoluble in water and to have a very unpleasant taste, therefore it cannot be used for aqueous liquid pharmaceutical forms, such as syrups, oral solutions, nasal drops, aqueous solutions for aerosol and nebulization.
It has been found that the verbenone-cyclodextrin complex has high water solubility and, moreover, verbenone unpleasant taste is no more perceptible. Therefore, the verbenone-cyclodextrin complex is a further object of invention. A further advantage of the complex of the invention is provided by its increased bioavailability.
The pharmaceutical forms comprising the verbenone- cyclodextrin complex can be prepared, for example, according to the methods described in "Remington's Pharmaceutical Sciences Handbook", Hack Pub. Co., USA.
Examples of pharmaceutical forms are capsules, pills, tablets, sugar-coated pills, granulates, syrups, drinkable solutions, nasal drops, solutions for aerosol or inhalation, suppositories, injectable solutions or suspensions both for the intravenous and the intramuscular routes.
The dosages will depend on the severity of the disorder, the age, weight and sex of the patient and on the clinician's advise. Examples of dosages comprise single or repeated administrations of the medicament containing verbenone or the verbenone-cyclodextrin complex so as to attain a daily dosage from 10 to 500 mg of the active ingredient. The preparation of the verbenone-cyclodextrin complex is illustrated in the
following examples.
EXAMPLE 1
A β-ciclodextrin amount equal to 0.1 mole is weighed and placed into a mortar of suitable size. Verbenone (0.1 mole), previously diluted with 15 ml of
96% ethanol, is added, and the mixture is mixed with a pestle to obtain an homogeneous mass. 20 ml of distilled water are added, and a mixture is obtained which hardens upon mixing. Said mixture is worked in a mortar for about 15 minutes, then it is dried in oven thermostatized at 60°C.
The obtained complex is in form of a flowing powder which is completely odourless.
Verbenone titre .80% on theoretical. EXAMPLE 2
5.80 g of verbenone were dissolved in 100 ml of 95°C ethanol (to obtain 50 g of a mixture), then they were added to 44.3 g of β-cyclodextrin in a round bottom flask. The mixture is evaporated to dryness, keeping temperature below 35°C, then it is placed into in a thermostatized oven at about 60°C until complete dryness. After drying, the product is sieved through a 16 mesh sieve.
The obtained product is an equimolar mixture (1:1) of verbenone and cyclodextrin (50 g theoretical, 49 g found).
EXAMPLE 3
68 g of β-Cyclodextrin are dispersed in 500 ml of distilled water (50 mmoles) and the solution is heated to 65eC. under stirring, until complete dissolution.
solution, with stirring. The mixture is left to cool t room temperature with stirring for 60 minutes, then i is kept at +4°C for 6 hours.
The solid phase is recovered by filtration and th solid is placed into a convection oven at 40°C for 18 hours, to obtain 64 g of a white powdery product, containing from 11.3 to 12.0% w/w of L-verbenone. Yield - 84.65%.
Claims
1. The use of [ (IS) (-)-4,6,6-trimethylbicyclo- (3,l,l)-hept-3-ene-2-one] of formula
for the preparation of a medicament having antielastase activity.
2. The use of [ (IS) (-)-4,6,6-trimethylbicyclo- (3,l,l)-hept-3-en-2-one] for the preparation of a medicament useful for the treatment of pulmonary emphysema.
3. The [ (IS) (-)-4,6,6-trimethylbicyclo-(3,l,l)-hept- 3-en-2-one]-cyclodextrin complex.
4. Pharmaceutical compositions containing the complex of claim 3.
5. Compositions according to claim 4, in form of capsules, pills, tablets, sugar-coated pills, granulates, syrups, drinkable solutions, nasal drops, solutions for aerosol or inhalation, suppositories, injectable solutions or suspensions • for both the intravenous and intramuscular routes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI912652A IT1251615B (en) | 1991-10-04 | 1991-10-04 | ANTIELASTASIC ACTIVITY MEDICATION. |
| ITMI912652 | 1991-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0565658A1 true EP0565658A1 (en) | 1993-10-20 |
Family
ID=11360822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP92920465A Withdrawn EP0565658A1 (en) | 1991-10-04 | 1992-09-30 | Verbenone, having antielastase activity, against pulmonary emphysema |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0565658A1 (en) |
| JP (1) | JPH06506500A (en) |
| AU (1) | AU2664492A (en) |
| CA (1) | CA2097611A1 (en) |
| IT (1) | IT1251615B (en) |
| WO (1) | WO1993006823A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7157446B2 (en) * | 2003-05-02 | 2007-01-02 | Bristol Myers Squibb Company | Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol |
| SG11201408108PA (en) | 2012-06-05 | 2015-02-27 | Univ Korea Res & Bus Found | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease |
| CN113603802B (en) * | 2021-08-24 | 2022-10-14 | 华侨大学 | Preparation method and application of verbena polysaccharide |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH625197A5 (en) * | 1976-06-03 | 1981-09-15 | Buskine Sa | Process for preparing verbenone, myrtenal and pinocarveol |
| WO1991004026A1 (en) * | 1989-09-14 | 1991-04-04 | Australian Commercial Research & Development Limited | Drug delivery compositions |
-
1991
- 1991-10-04 IT ITMI912652A patent/IT1251615B/en active IP Right Grant
-
1992
- 1992-09-30 AU AU26644/92A patent/AU2664492A/en not_active Abandoned
- 1992-09-30 WO PCT/EP1992/002269 patent/WO1993006823A1/en not_active Application Discontinuation
- 1992-09-30 CA CA002097611A patent/CA2097611A1/en not_active Abandoned
- 1992-09-30 JP JP5506603A patent/JPH06506500A/en active Pending
- 1992-09-30 EP EP92920465A patent/EP0565658A1/en not_active Withdrawn
Non-Patent Citations (1)
| Title |
|---|
| See references of WO9306823A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ITMI912652A1 (en) | 1993-04-04 |
| CA2097611A1 (en) | 1993-04-04 |
| WO1993006823A1 (en) | 1993-04-15 |
| AU2664492A (en) | 1993-05-03 |
| ITMI912652A0 (en) | 1991-10-04 |
| JPH06506500A (en) | 1994-07-21 |
| IT1251615B (en) | 1995-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007524627A5 (en) | ||
| Giraldi et al. | Antitumour action of rhodium (I) and iridium (I) complexes | |
| US5922689A (en) | Cisplatin analogs for cancer treatment | |
| EP0565658A1 (en) | Verbenone, having antielastase activity, against pulmonary emphysema | |
| WO1998008831A1 (en) | Preventive or remedy for alzheimer's disease | |
| JPH0267218A (en) | Virus genome inactivator | |
| JP3084062B2 (en) | How to use 2-phenyl-1,2-benzisoselenazol-3 (2H) -one | |
| WO2009003656A1 (en) | Cyclodextrin-based nanosponges as a vehicle for antitumoral drugs | |
| JP4235111B2 (en) | Supramolecular carboplatin derivative, process for producing the same, pharmaceutical composition containing the derivative as an active ingredient and use thereof | |
| US3839317A (en) | Digoxin complexes | |
| XU et al. | Study on the mechanism of astragalus glycyrrhiza decoction regulating SIRT1/FOXO1 pathway to prevent QT interval prolongation induced by arsenic trioxide based on metabolomics | |
| Han et al. | A Deep Insight into Ferroptosis in Renal Disease: Facts and Perspectives | |
| RU2784809C2 (en) | Combined product containing dicycloplatin and method for its production and use | |
| JPH05112596A (en) | Medicine containing bufalin and bufadienolide as effective components | |
| JP2001253823A (en) | Hiv gene expression inhibitor | |
| JPS6144897A (en) | 5-fluorouracil derivative and medical drug containing same | |
| JP2016145175A (en) | Inhibitors which inhibit amyloid fiber formation, decomposers which disassemble amyloid fibers, medicaments for prevention, therapy, or progressive inhibition of neurodegenerative disease, and production methods of inhibitor and decomposer | |
| Sartori et al. | Early and late hyperferremia during cisplatin chemotherapy | |
| Sieradzan et al. | Comparative effects of cefoxitin and cefotetan on vitamin K metabolism | |
| JPS6357519A (en) | Agent for suppressing carcinogenic promotor | |
| JPH046705B2 (en) | ||
| JPH02304024A (en) | Agent for suppressing proliferation of aids virus | |
| RU2495674C1 (en) | Method for preparing drug possessing antiulcerogenic, antistress and hemostatic activities | |
| JPS6272620A (en) | Preventive and remedy for disseminating vascular coagulation syndrome | |
| JP2000154145A (en) | Urease inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE |
|
| 17P | Request for examination filed |
Effective date: 19930922 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: FLARER S.A. PHARMACEUTICAL FINE CHEMICALS |
|
| 17Q | First examination report despatched |
Effective date: 19980224 |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19990814 |